Charles Zhu
Stock Analyst at Guggenheim
(2.73)
# 2,043
Out of 5,044 analysts
27
Total ratings
52.17%
Success rate
21.76%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Charles Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNGX Tango Therapeutics | Maintains: Buy | $10 → $12 | $7.83 | +53.26% | 4 | Oct 24, 2025 | |
| MRUS Merus | Downgrades: Market Perform | $97 | $94.81 | +2.31% | 7 | Sep 30, 2025 | |
| CBIO Crescent Biopharma | Initiates: Outperform | $22 | $12.50 | +76.00% | 1 | Jun 18, 2025 | |
| RPTX Repare Therapeutics | Downgrades: Market Perform | n/a | $1.78 | - | 1 | Dec 13, 2024 | |
| MGNX MacroGenics | Upgrades: Buy | $12 | $1.69 | +610.06% | 4 | Nov 7, 2023 | |
| NUVL Nuvalent | Initiates: Buy | $56 | $102.97 | -45.62% | 1 | Jul 24, 2023 | |
| TARA Protara Therapeutics | Assumes: Buy | $22 | $5.20 | +323.08% | 1 | Jul 10, 2023 | |
| COGT Cogent Biosciences | Reiterates: Buy | $26 | $16.00 | +62.50% | 3 | Jun 13, 2023 | |
| IDYA IDEAYA Biosciences | Reiterates: Buy | $32 | $32.18 | -0.56% | 3 | Mar 8, 2023 | |
| ZYME Zymeworks | Upgrades: Buy | $14 | $19.38 | -27.76% | 2 | May 5, 2022 |
Tango Therapeutics
Oct 24, 2025
Maintains: Buy
Price Target: $10 → $12
Current: $7.83
Upside: +53.26%
Merus
Sep 30, 2025
Downgrades: Market Perform
Price Target: $97
Current: $94.81
Upside: +2.31%
Crescent Biopharma
Jun 18, 2025
Initiates: Outperform
Price Target: $22
Current: $12.50
Upside: +76.00%
Repare Therapeutics
Dec 13, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.78
Upside: -
MacroGenics
Nov 7, 2023
Upgrades: Buy
Price Target: $12
Current: $1.69
Upside: +610.06%
Nuvalent
Jul 24, 2023
Initiates: Buy
Price Target: $56
Current: $102.97
Upside: -45.62%
Protara Therapeutics
Jul 10, 2023
Assumes: Buy
Price Target: $22
Current: $5.20
Upside: +323.08%
Cogent Biosciences
Jun 13, 2023
Reiterates: Buy
Price Target: $26
Current: $16.00
Upside: +62.50%
IDEAYA Biosciences
Mar 8, 2023
Reiterates: Buy
Price Target: $32
Current: $32.18
Upside: -0.56%
Zymeworks
May 5, 2022
Upgrades: Buy
Price Target: $14
Current: $19.38
Upside: -27.76%